Date: Sunday, November 5, 2017
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an inflammatory disease characterized by changes in the osteoproliferative process, a dysregulation in the molecules involved in bone remodeling is highly plausible in these patients, also affecting vascular calcification in the context of atherosclerosis. Therefore, we aimed to assess the role of osteonectin (ON), osteopontin (OPN) and osteocalcin (OC), implicated in bone metabolism2, in the development of subclinical atherosclerosis and its association with CV risk factors in a large cohort of axSpA patients.
Methods: Serum ON, OPN and OC levels were measured by multiplex assays in 171 Spanish axSpA patients (including both non-radiographic axSpA [nr-axSpA] and AS), recruited from Hospital Universitario Marqués de Valdecilla and Hospital de Laredo (Spain) who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria (for nr-axSpA)3 and also the 1984 modified New York criteria (for AS)4. Patients with history of CV disease, diabetes mellitus, chronic kidney disease, IBD or psoriasis were excluded. Carotid US was performed to evaluate the presence of subclinical atherosclerosis. The association of these molecules with the different variables of study were assessed by ANOVA, partial correlation or Student`s t test, where appropriate, using STATA® v. 11.1. The results were adjusted by potential confounding factors.
Results: ON and OPN positively associated with ESR at study (p=0.01 and 0.02). Higher ON levels were observed in men and axSpA patients who smoked (p=0.01), and also correlated with CRP levels at study (p=0.02). In addition, patients with CRP at diagnosis >3 mg/L showed higher OPN levels. Regarding OC, hypertensive patients displayed higher levels of this molecule (p=0.02). No association was found between these molecules and markers of subclinical atherosclerosis.
Conclusion: We disclosed an association of ON, OPN and OC with inflammation and CV risk factors, supporting an implication of these molecules in the development and progression of atherosclerotic disease in axSpA.
 Joint Bone Spine 2014;81(1):57-63.  Clin Chim Acta 2015;438:401-14.  Ann Rheum Dis 2009;68:777–83.  Arthritis Rheum 1984;27:361-8.
FG is a recipient of a Sara Borrell post-doctoral fellowship from the Instituto de Salud Carlos III (ISCIII)(Spain)(CD15/00095). SR-M is supported by the RETICS Program (RIER) (ISCIII, Spain)(RD16/0012/0009). RL-M is supported by a Miguel Servet type I programme (ISCIII, Spain)(CP16/00033). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
To cite this abstract in AMA style:Genre F, Rueda-Gotor J, Irure-Ventura J, Remuzgo-Martínez S, Corrales A, Ubilla B, Mijares V, Fernández-Díaz C, Portilla V, Blanco R, Llorca J, Ocejo-Vinyals JG, López-Mejías R, González-Gay MA. Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/association-of-osteonectin-osteopontin-and-osteocalcin-with-inflammation-and-cardiovascular-risk-in-patients-with-axial-spondyloarthritis/. Accessed September 25, 2021.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-osteonectin-osteopontin-and-osteocalcin-with-inflammation-and-cardiovascular-risk-in-patients-with-axial-spondyloarthritis/